HVIVO PLC Logo

HVIVO PLC

A contract research organization specializing in human challenge trials for biopharma.

HVO | IL

Overview

Corporate Details

ISIN(s):
GB00B9275X97
LEI:
213800VT5KBM7JLIV118
Country:
United Kingdom
Address:
QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON

Description

hVIVO plc is a full-service contract research organization (CRO) and a leading specialist in human challenge trials. The company provides end-to-end clinical development solutions for a global biopharma client base, focusing on infectious and respiratory diseases. Its services span from preclinical consultancy to Phase III clinical trials, including first-in-human studies, biometry, and consulting. hVIVO operates a state-of-the-art quarantine facility in London and provides advanced laboratory services under its hLAB brand. Through subsidiaries such as CRS and Venn Life Sciences, it offers early-phase clinical trial expertise and patient recruitment across multiple clinical sites. The company's integrated approach is designed to accelerate the development of vaccines and therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 08:30
MSD to acquire Cidara
English 20.0 KB
2025-11-20 08:20
>£5 million CRS contracts signed
English 20.5 KB
2025-11-11 08:25
Positive data from novel human challenge models
English 23.6 KB
2025-11-06 18:15
Holding(s) in Company
English 22.7 KB
2025-11-03 08:30
Presentation at Jefferies Healthcare Conference
English 17.0 KB
2025-09-23 08:00
Interim results
English 206.9 KB
2025-09-04 08:00
Notice of Results
English 18.1 KB
2025-07-29 08:00
Proposed appointment of Chair
English 16.3 KB
2025-07-22 08:00
H1 Trading update
English 26.7 KB
2025-07-18 08:00
Directorate Change
English 16.4 KB
2025-07-09 08:00
Notice of Trading Update
English 17.4 KB
2025-07-01 17:04
Holding(s) in Company
English 24.3 KB
2025-06-30 08:00
Positive results from client Phase 2b field study
English 22.0 KB
2025-06-05 14:00
Result of AGM
English 15.3 KB
2025-06-02 08:00
Director/PDMR Shareholding
English 48.9 KB

Automate Your Workflow. Get a real-time feed of all HVIVO PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HVIVO PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HVIVO PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150
ONCODESIGN Logo
Develops therapeutic and diagnostic solutions for resistant and metastatic cancers.
France
ALONC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.